...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis.
【24h】

Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis.

机译：与肺切除术相比，伴有或不伴有肺动脉重建术的双肺叶切除术（双袖）是否对非小细胞肺癌有良好的疗效？荟萃分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It has been reported that sleeve lobectomy (SL) concomitant with or without pulmonary artery reconstruction (PAR) might be an alternative procedure for pneumonectomy (PN) in non-small cell lung cancer (NSCLC). The aim of this study was to assess whether SL or PN offers a low morbidity and mortality and better long-term survival. We performed a meta-analysis of studies published in English between 1996 and 2006 to comprehensively compare the postoperative mortality, morbidity, locoregional recurrences, and time-to-event outcomes of SL and PN in NSCLC, and reviewed the recent literatures on PAR in the corresponding period as well. Twelve studies met the defined criteria including a total of 2984 subjects, and five studies for PAR. The odds ratio for postoperative mortality (SL vs PN) was 0.65 (95% confidence interval (CI): 0.42-1.01), 1.01 (95% CI: 0.70-1.44) for postoperative complications, and 0.91 (95% CI: 0.45-1.82) for locoregional recurrences. The weighted mean operative mortality for PAR was 3.3%,and 32.4% for complications. The estimated combined hazard ratio for overall survival in 10 studies was 0.70 (95% CI: 0.62-0.79) in favor of SL group. The median overall survival was 60 months for the SL group, 26 months for the PN group, and 30 months for PAR group. Survival difference in patients with pN0 or pN1 at 1 year demonstrated a pooled risk difference (SL vs PN) of 0.03 (95% CI: -0.08-0.13), 0.13 (95% CI: 0.00-0.25) in patients with pN2 at 1 year, 0.21 (95% CI: 0.07-0.36) in patients with pN0 or pN1 at 5 years, and 0.06 (95% CI: -0.10-0.21) in patients with pN2 at 5 years. Our results suggests that SL with or without PAR can be accomplished safely in selected patients without increasing the morbidity and mortality as compared to PN, that SL even with PAR offers better long-term survival than does PN, and that a more radical operation such as PN is not a more appropriate procedure, even in higher stage tumors.
机译：据报道，伴有或不伴有肺动脉重建（PAR）的袖状叶切除术（SL）可能是非小细胞肺癌（NSCLC）肺切除术（PN）的另一种手术方法。这项研究的目的是评估SL或PN是否具有较低的发病率和死亡率以及更好的长期生存率。我们对1996年至2006年间以英语发表的研究进行了荟萃分析，以全面比较NSCLC中SL和PN的术后死亡率，发病率，局部复发和事件发生时间，并回顾了近期关于PAR的文献。相应的时期也是如此。十二项研究符合既定标准，包括总共2984名受试者，以及五项针对PAR的研究。术后死亡率的比值比（SL与PN）为0.65（95％置信区间（CI）：0.42-1.01），1.01（95％CI：0.70-1.44）和术后并发症为0.91（95％CI：0.45-） 1.82）对于局部复发。 PAR的加权平均手术死亡率为3.3％，并发症为32.4％。有利于SL组的10项研究的总生存率综合风险比估计为0.70（95％CI：0.62-0.79）。 SL组的中位总生存期为60个月，PN组为26个月，PAR组为30个月。 1年时pN0或pN1患者的生存差异显示合并风险差异（SL vs PN）为0.03（95％CI：-0.08-0.13），0.13（95％CI：0.00-0.25）在pN2为1的患者中5年时pN0或pN1患者为0.21（95％CI：0.07-0.36），5年时pN2患者为0.06（95％CI：-0.10-0.21）。我们的结果表明，与PN相比，具有或不具有PAR的SL可以在选定的患者中安全完成，而不会增加发病率和死亡率，即使具有PAR的SL也比PN具有更好的长期存活率，并且更彻底的手术如PN并不是更合适的方法，即使在晚期肿瘤中也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号